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Abstract: Schizophrenia is a disabling psychiatric illness associated with disruptions in cog-
nition, emotion, and psychosocial and occupational functioning. Increasing evidence shows 
that psychosocial interventions for people with schizophrenia, as an adjunct to medications 
or usual psychiatric care, can reduce psychotic symptoms and relapse and improve patients’ 
long-term outcomes such as recovery, remission, and illness progression. This critical review 
of the literature was conducted to identify the common approaches to psychosocial interven-
tions for people with schizophrenia. Treatment planning and outcomes were also explored and 
discussed to better understand the effects of these interventions in terms of person-focused 
perspectives such as their perceived quality of life and satisfaction and their acceptability 
and adherence to treatments or services received. We searched major health care databases 
such as EMBASE, MEDLINE, and PsycLIT and identified relevant literature in English from 
these databases. Their reference lists were screened, and studies were selected if they met 
the criteria of using a randomized controlled trial or systematic review design, giving a clear 
description of the interventions used, and having a study sample of people primarily diagnosed 
with schizophrenia. Five main approaches to psychosocial intervention had been used for the 
treatment of schizophrenia: cognitive therapy (cognitive behavioral and cognitive remediation 
therapy), psychoeducation, family intervention, social skills training, and assertive community 
treatment. Most of these five approaches applied to people with schizophrenia have demon-
strated satisfactory levels of short- to medium-term clinical efficacy in terms of symptom 
control or reduction, level of functioning, and/or relapse rate. However, the comparative effects 
between these five approaches have not been well studied; thus, we are not able to clearly 
understand the superiority of any of these interventions. With the exception of patient relapse, 
the longer-term (eg, .2 years) effects of these approaches on most psychosocial outcomes 
are not well-established among these patients. Despite the fact that patients’ perspectives on 
treatment and care have been increasingly concerned, not many studies have evaluated the 
effect of interventions on this perspective, and where they did, the findings were inconclusive. 
To conclude, current approaches to psychosocial interventions for schizophrenia have their 
strengths and weaknesses, particularly indicating limited evidence on long-term effects. To 
improve the longer-term outcomes of people with schizophrenia, future treatment strategies 
should focus on risk identification, early intervention, person-focused therapy, partnership 
with family caregivers, and the integration of evidence-based psychosocial interventions into 
existing services.
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Introduction
Schizophrenia is characterized by profound disruptions to 
cognition and emotions, often resulting in progressive loss 
of self-care and social functioning in affected individuals. 
As discussed in another review, “Current approaches to 
treatments for schizophrenia spectrum disorders, part I: an 
overview and medical treatments,”1 a narrowly focused bio-
logical model has been shown to be inadequate if treatment 
and care for schizophrenia and these patients’ potential are 
to be optimized. Although psychopharmacological treat-
ment is essential and considered the mainstay for achieving 
better physical and cognitive functioning in schizophrenia, 
several limitations such as unavoidable adverse effects (eg, 
acute extrapyramidal symptoms and other neurocogni-
tive impairments in long-term treatment with these drugs) 
and medication refusal or noncompliance have reduced its 
efficacy in the treatment of schizophrenia.1,2 The optimism 
that medication use alone can result in full recovery, early 
discharge, or reduced risk for relapse is not justified in 
many cases. Recent guidelines on treatment and care for 
schizophrenia have recommended that sufficient knowledge 
about the illness and its treatments and other strategies in 
psychosocial and/or person-focused interventions should be 
provided to patients (and/or their family carers) to maximize 
their acceptance and satisfaction with the treatments and 
to improve the experience and outcomes of care for these 
patients.2,3 Health professionals should work in partnership 
with patients and their family carers, offering treatment, 
education, support, and psychosocial care in an atmosphere 
of hope and optimism.4
During the last three decades, clinical research has 
increasingly indicated that community-based psychosocial 
interventions can improve the longer-term outcomes of 
patients with schizophrenia and other severe mental illnesses. 
A critical review of the common approaches to psychosocial 
intervention for people with schizophrenia was therefore per-
formed. First, the concepts and research evidence of five main 
approaches to psychosocial interventions for schizophrenia 
(ie, cognitive therapy, psychoeducation programs, family 
intervention, social skills training programs, and assertive 
community treatment [ACT]) are discussed. Second, this 
review provides a summary of and discussion on the relative 
efficacy of the most commonly used approaches to psychoso-
cial interventions in terms of their effect sizes on their most 
commonly reported patient outcomes. Third, the importance 
of person-focused perspectives such as quality of life, patient 
satisfaction and acceptability, and adherence to treatment 
and its use in research on psychosocial interventions for 
schizophrenia are also discussed. Finally, we have made 
several recommendations for best practice in schizophrenia 
treatment on the basis of this review, as well as another 
related review published in Neuropsychiatric Disease and 
Treatment.1 These findings and discussions can increase our 
understanding of the most effective means for people with 
schizophrenia to be better managed within the community, 
as well as suggesting ways to improve community-based 
interventions and rehabilitation for schizophrenia.
Psychosocial interventions  
for people with schizophrenia
Recent research and systematic reviews suggest that both 
pharmacological and psychosocial treatment, offered early 
to people presenting with schizophrenia and other psychotic 
disorders, can improve their prognosis and even help prevent 
their illness chronicity.5–7 There has also been increasing evi-
dence that psychosocial interventions are effective in reliev-
ing these patients’ psychotic symptoms and improving their 
functioning, thus providing support for recommendations 
that they be considered an indispensable part of the treat-
ment options available for promoting patient recovery from 
schizophrenia. It is suggested that psychosocial interventions 
can not only directly address a wide range of patients’ health 
needs, such as symptom reduction, relapse, and treatment 
adherence, but also provide a more cost-effective intervention 
than the standard treatment for schizophrenia.8
Five major categories of psychosocial intervention have 
been used in the community-based treatment of patients 
with schizophrenia, with evidence of efficacy on relapse 
prevention and symptom control. The five categories are 
cognitive therapy (mainly cognitive behavioral therapy 
[CBT] and cognitive remediation therapy), psychoeduca-
tion programs, family intervention, social skills (and other 
coping skills), training programs, and case management or 
ACT.9,10 Nevertheless, there are also a few other traditional 
approaches to psychosocial interventions, such as psycho-
dynamic psychotherapy;11,12 client-centered, supportive, and 
insight-oriented psychotherapy;13–15 and behavioral modifi-
cation techniques (eg, token economy),16,17 which have been 
believed to be potentially effective but are lacking empirical, 
systematic outcome studies that support each as an evidence-
based intervention for schizophrenia.
Even though the process of these interventions is not 
always described clearly, each type of intervention model 
has an individual set of goals and objectives, as well as a 
treatment agenda, and all have been found to be effective 
in improving different aspects of the functioning of patients 
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with schizophrenia. However, it should be noted that there are 
difficulties in implementing these interventions in everyday 
clinical practice in community care settings. First, staff may 
not be adequately trained to implement the intervention. 
Second, as these interventions need to be implemented 
for 9–12 months, there may be insufficient resources to 
deliver and evaluate them adequately.18 Finally, there may be 
inadequate recognition and support from service managers 
in terms of the service strategy collaboration, resources, and 
time needed to embed these interventions in existing mental 
health services.4,19
For this literature review, electronic searches of the most 
common and major databases were performed. These data-
bases included Biological Abstracts (1980–2012), CINAHL 
(1982–2012), the Cochrane Library and Cochrane Schizo-
phrenia Group’s Register of Trials, EMBASE (1980–2012), 
MEDLINE (1966–2012), PsycLIT (1887–2012), SIGLE 
(1990–2012), and Sociofile (1980–2012). Keywords used 
for the searches were “schizophrenia,” “psychosocial inter-
vention or program,” “psychological treatment or therapy,” 
“psychotherapy,” “cognitive or cognitive behavior therapy,” 
“skills training,” “psycho-education,” “family intervention,” 
and “case management or assertive treatment.” There were 
472 articles retrieved from the initial searches. After initial 
screening of the abstracts, those found relevant to the topic 
of interest (n = 145) were reviewed and checked for method-
ological rigor and validity by two authors; only randomized 
controlled trials and review articles and those studies with 
a primary diagnosis of schizophrenia or its subtypes were 
considered for inclusion. All reference lists of the selected 
articles were also searched to identify further relevant trials. 
Finally, there were 92 articles included in this review, includ-
ing 25 for psychoeducation, 22 for CBT, 15 for family inter-
vention, 10 for cognitive remediation therapy, and 7 for social 
skills training. Among them, 15 were review articles.
Cognitive therapy
CBT
Developed in the 1950s, CBT has been considered an effec-
tive therapy for depressive disorder for several decades; 
this therapy and some of its well-established techniques 
have eventually come to be used as a promising treatment 
modality for individuals with schizophrenia whose psychotic 
symptoms are not controlled by medication.20 CBT is a 
highly structured and standardized therapy to help patients 
with schizophrenia cope with their psychotic symptoms by 
examining and reevaluating their thoughts and perceptions 
of experiences. It can only be successful if the therapist 
accepts the patient’s perception of reality (and the illness 
and its symptoms) and determines how to use this “misinter-
pretation” to assist the patient in correctly managing his/her 
life problems.21 In CBT, the patient would be encouraged to 
actively participate by examining the evidence for and against 
the distressing belief, challenging the habitual patterns of 
thinking about the belief, and using reasoning and personal 
experiences to develop rational and acceptable alternative 
explanations and interpretations for coping, problem solv-
ing, and self-management of the illness and its symptoms. 
Although some studies have found CBT to have positive 
benefits in terms of reduction of positive symptoms and 
recovery time over the course of 9–12 months in comparison 
with standard care and a few psychological approaches, it has 
not yet shown promising evidence of reduction of negative 
and persistent severe psychotic symptoms for people with 
schizophrenia, particularly over a longer-term (ie, 2-year) 
follow-up.22,23 Although CBT for schizophrenia was mainly 
designed with an individual treatment, there has been some 
evidence its group delivery may be more cost-effective.24
Previous prospective, nonrandomized controlled trials of 
CBT for schizophrenia in the 1990s also indicated several 
limitations, including small sample sizes (eg, 3–30 patients 
per group), lack of other psychosocial interventions for 
comparison, lack of blinding for independent assessors, and 
lack of validity and fidelity checking of the intervention 
sessions. Although the effect sizes for improving the posi-
tive symptoms in more recent randomized controlled trials 
(2000–2006) were mainly very low to medium (ie, 0.02–0.62; 
mean weight effect size, 0.37), there were no significant 
differences in target symptoms (both positive and negative) 
between individual and group CBT.24–27 In addition, con-
trolled trials of CBT for relapse prevention have yielded 
inconsistent findings. Gumley et al28 showed the significant 
effect of CBT in identifying prodromal signs of relapse 
from schizophrenia during a 12-month follow-up, whereas 
Durham et al29 found a modest effect in relapse prevention 
and reduction of positive symptoms with newly trained and 
minimally supervised therapists for psychosis.
Overall, the research evidence on CBT favors its use 
among people with schizophrenia, and it is recommended 
in the United Kingdom and United States that it be included 
as the main approach to interventions for schizophrenia.2,3 
Although there are differences in duration, number of ses-
sions, comparative treatment, and outcomes in controlled tri-
als, recent systematic reviews of these trials reported a similar 
significant positive effect of CBT on improving psychotic 
symptoms over the course of 6–12 months  follow-up when 
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compared with standard psychiatric care.28,29 In seven 
controlled trials reviewed by Gould et al,30 CBT can also 
produce a large effect size in residual or persistent positive 
symptoms immediately after the intervention (effect size, 
0.65) and over the course of 1 year (effect size, 0.93).
A specific technique used in CBT for patients with schizo-
phrenia is the normalizing rationale, in which the patient 
with poor coping ability and social withdrawal from mental 
health services is empowered and facilitated to collaboratively 
develop effective coping strategies, leading to symptomatic 
improvement.22,23 Tarrier et al24 conducted a multicenter ran-
domized controlled trial with an 18-month follow-up of CBT 
for in-hospital patients with acute schizophrenia and reported 
that CBT was more effective in symptom control than routine 
care. However, there were no significant differences on relapse, 
rehospitalization, or level of functioning between groups. 
Similar to the findings of the recent systematic reviews,21–23,26 
the evidence identified for the effectiveness of CBT in terms 
of controlling positive, negative, and mood-related symptoms 
and relapse prevention, particularly in terms of the specificity 
and durability of these intended benefits, is not conclusive or 
consistent. When compared with supportive psychotherapy 
and psychoeducation, CBT for schizophrenia showed rela-
tively lower effects on relapse, reduction of rehospitalization, 
and mental state both medium term (6 weeks–3 months) and 
long term (.3 months–1 year).21,22
In addition, CBT requires experienced and skilled prac-
titioners, a clear definition of the essential and effective 
components in the intervention, and management of the 
practical demands on patients in terms of time for regular 
sessions and the necessity for high levels of concentration 
and insight. As Tarrier et al31 and Turkington et al32 point 
out, these requirements exclude a high proportion of more 
disabled patients and limit its widespread dissemination into 
routine practice. These contradictory findings and limitations 
of CBT for schizophrenia reveal a need for more random-
ized controlled trials focusing on the durability of the effect, 
with an expansion of the targeted symptoms, including 
negative symptoms, depression, and anxiety. As suggested 
by Barrowclough et al33 and Addington et al,34 CBT could 
be used as an adjunct to other psychosocial interventions to 
improve symptoms or psychosocial functioning, particularly 
for young people with a high risk for psychosis or for those 
with a dual diagnosis and/or substance abuse. For instance, 
although cognitive remediation focuses on neurocognition 
and social cognition, there is a possibility of synergy with 
CBT for improving the cognitive and social functioning of 
patients with schizophrenia.
Cognitive remediation therapy
In response to the impaired cognition that occurs in many 
patients with schizophrenia, recent research has also raised 
concerns about the aspects of psychomotor function, 
attention, working memory, executive function, and other 
cognitive functions. These impairments could persist in the 
course of schizophrenia, limiting the psychosocial and work 
functioning of the patients, and thus reducing the efficacy of 
CBT, which requires high levels of self-monitoring, attention, 
rational thought, and insight into the illness and its symptoms. 
As a result, several approaches to cognitive remediation have 
been developed since the 1990s to enhance executive func-
tion and social cognition through information restructuring 
or reorganization, effective use of environmental aids and 
probes, and a wide range of techniques concerning cognitive 
functioning (mainly neurocognition and social cognition).
Neurocognition refers to the basic cognitive processes 
involved in thinking and reasoning and supporting attention, 
memory, and executive function abilities.35 Social cognition is 
defined by the cognitive abilities that support the processing, 
interpretation, and regulation of socioemotional information, 
which involves perspective taking, theory of mind, emotional 
perception and regulation, social cue recognition, and casual 
attributions of social phenomena.36 Despite a variety of cogni-
tive remediation approaches or techniques for schizophrenia, 
a set of practice principles has emerged, including develop-
ment of mental strategies to optimize cognitive performance 
and task completion, repetition of cognitive exercises on key 
and complex targeted tasks, progression of targeted cognitive 
abilities from basic to complex ones, use and gradual remov-
als of external aids (mainly auditory and visual) to support 
cognitive performance, adjustment of difficulty and linking 
of cognitive exercises to real-world behaviors and domains of 
functioning, and integration of these cognitive performances 
with other treatments.37 Impairments in social cognition 
appear to have negative effects on interpersonal relationships, 
community adjustment, and vocational functioning, and thus 
functional recovery in schizophrenia.38
Most recent controlled trials have used only cognitive 
remediation for cognitive rehabilitation of people with schizo-
phrenia and have shown its medium-sized effects (effect size, 
0.30–0.48) in improving attention, processing and working 
memory, and executive functioning.39 Despite the inconsis-
tent and questionable generalizability and durability of the 
benefits found in cognitive and other functional outcomes, 
one recent meta-analysis of 26 controlled trials (involving 
around 1,150 patients) proposed that cognitive remediation 
could significantly improve cognitive performance (effect 
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size, 0.41), psychosocial functioning (effect size, 0.36), and 
psychotic symptoms (effect size, 0.28) in people with schizo-
phrenia during a short-term (eg, 1 year) follow-up.39 Similar 
to the findings of another meta-analysis on 40 controlled 
trials in 2011,40 it is suggested that cognitive remediation 
can produce moderate improvements in global cognition and 
functioning when it is provided together with other strategies 
in psychiatric rehabilitation, such as vocational training, or 
when patients are mentally stable. Although effect sizes did 
not differ in terms of types of remediation training used, 
a larger effect size in verbal memory was associated with 
more time of remediation training.39 Although the effects of 
most cognitive remediation programs on most domains of 
basic cognitive functioning are significant but modest, the 
intervention is likely to be more successful when the skills 
trained closely relate to those needed in individual patients’ 
daily living, thus reflecting how patient variables such as 
intrinsic motivation may interact with the training to produce 
an optimal response to cognitive remediation.41
Fewer studies on social cognition training are found. 
Two recent clinical trials of 12-week individual-based and 
20-week group-based (ie, Social Cognition and Interaction 
Training) social cognition training programs, both with 
31 outpatients with schizophrenia, found significant improve-
ments in emotional perception.42,43 Another controlled trial 
compared the effect on social competence and social and 
occupational functioning between a 12-session social cogni-
tive training program (ie, Training of Affect Recognition) 
and another 12-session remediation training program among 
38 patients with schizophrenia spectrum disorders.44 The 
findings indicate that the social cognitive training program 
demonstrated significantly greater improvements in social 
functioning and competence than neurocognition training 
at the completion of the intervention. Although there were 
no significant effects found on some domains of social 
recognition and emotional functioning in this and most 
previous studies of social cognitive training, more broad-
based approaches with a combination of training in social 
cognitive, neurocognitive, and behavioral skills are recom-
mended to enhance its effect on more functional outcomes 
in schizophrenia.
A few cognitive enhancement programs such as Cognitive 
Enhancement Therapy45 and Social Cognition and Interaction 
Training43 have been designed to provide enriched cognitive 
training and experiences through integrated neurocognition 
and social cognitive training strategies. More research with 
longer follow-up and larger, diverse samples is recommended 
to conclusively show the substantive positive effects of these 
integrated cognitive remediation training programs and its 
active components among people with schizophrenia spec-
trum disorders.
Psychoeducation programs
The psychoeducational model of patient care, as conceptu-
alized by its pioneers, focused on the plight of people with 
mental illness, particularly on their higher risk for relapse 
and rehospitalization and its considerable cost to the patient 
and to society as a whole.46 Although psychoeducation is 
broadly used to characterize a range of approaches of edu-
cational intervention for patients with schizophrenia, there 
are several features common to the effective ones, includ-
ing structural components, philosophical perspectives, and 
the goals and content of the programs. First, their common 
structural components are that the programs are designed and 
led by health professionals; they are mainly medium term, 
lasting between 9 months and 2 years; they are an integral 
part of the patient’s treatment plan, along with medication 
and other psychiatric treatments; they may be delivered to 
single or multiple participants at the patient’s home or in a 
clinical setting; and they mainly include both the patient and 
his/her family members during the intervention sessions.47 
Second, the philosophical perspectives of these interventions 
are common in their emphasis on the present situation and 
improving the future while avoiding delving into the past 
and placing blame.48 The treatment team seeks to establish 
a collaborative relationship with the patient and/or family to 
share the burden of managing the illness and working toward 
patient recovery. Last, in terms of the goals and content of 
the programs, all focus on providing information about the 
illness and its treatment, management of the patient’s ill-
ness behavior, problem-solving and coping skills in illness 
management, and access to community mental health care 
services.49 Such information is crucial in enabling these 
patients to cope with the illness and its management.
It is also believed that psychoeducation for the family 
members of these patients is useful and effective in improving 
patient outcomes because a positive and supportive family 
environment and behaviors can encourage patients and enable 
them to improve their functioning and self-management 
of the illness, thus reducing their likelihood of relapse.2 With 
the strategies and skills taught in coping with schizophrenia, 
psychoeducation programs for both patients and their family 
members have accumulated much evidence regarding their 
efficacy in overall mental state, treatment compliance, relapse 
prevention, and satisfaction with mental health services,50 
and it is therefore suggested that they be integrated into a 
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family-based or multicomponent psychosocial intervention 
(including illness management, supported employment, and 
interpersonal and social skills training for both patients and 
their families), as well as the standard care, for more effective 
and longer-term patient outcomes.
During the last 20 years, several models of psychoeduca-
tion for schizophrenia have been developed and empirically 
tested. The theoretical foundations for these interventions 
are mainly derived from stress vulnerability and coping 
models and other psychological theories such as cognitive–
behavioral, social learning, and crisis theories.51 Teaching 
patients (and their families) in a variety of forms accord-
ing to the ability and interest of the individual or group of 
patients with a view to improving their treatment compliance 
and illness management is the main goal in mental health 
care to minimize relapse and optimize the patients’ health 
condition. Nevertheless, some studies indicate that psycho-
education alone enhanced patients’ knowledge about the 
illness but could not improve other patient outcomes or their 
behaviors.52,53 The nonsignificant changes in psychosocial 
functioning and illness-related behaviors could be a result 
of their lack of attention and emphasis on the adequate dose 
(length) of education and skills practice, as well as the inflex-
ibility of the learning process through progressive changes 
in behavior, skill, and attitude.50
A recent systematic review of 44 randomized controlled 
trials conducted between 1988 and 2009 indicated that people 
with schizophrenia (n = 1,200–1,400) in psychoeducation 
programs for schizophrenia reported a significant increase 
in treatment compliance and reduction in readmission and 
relapse rates in the short term (ie, within 6 months) when 
compared with those receiving standard psychiatric care.50 
Psychoeducation also promoted social and global function-
ing. In the medium term (ie, 6–18 months), it was found 
that when treating four participants with psychoeducation 
instead of standard care, one additional person would show a 
significant improvement in medication compliance, relapse, 
and knowledge about the illness. In addition, the participants 
(n = 236) who received psychoeducation were also more 
likely to be satisfied with mental health services in the short 
term and with improved quality of life in the medium term. 
Although most of the 44 trials reported favorable results for 
psychoeducation, it is noteworthy that there were no signifi-
cant differences in their primary outcomes (ie, compliance, 
relapse, and mental state) between psychoeducation and 
standard care across countries. The review also noted that a 
majority of the studies reviewed were conducted in hospitals, 
whereas most people with schizophrenia are taken care of in 
the community. It is recommended that further research be 
conducted to test the efficacy of psychoeducation in the con-
text of community mental health care to understand and apply 
its “true” effect to the current community-based care.
A prospective randomized study by Feldmann et al51 
examined the influence of pretherapy duration of illness 
on the effects of psychoeducation for 191 outpatients with 
schizophrenia in Germany. Psychoeducation showed the most 
preventive effect in patients with a medium duration of illness 
(eg, 2–4 years) who had already accepted their illness but 
were not yet adhering to fatalistic assumptions often estab-
lished to explain the manifestation of illness as nonretractable 
and unrecoverable. A randomized, multicenter controlled trial 
based in Munich, Germany, showed that psychoeducation for 
schizophrenia, consisting of individual behavioral therapy, 
self-assertive and problem-solving training, communication 
skills training, and further family therapy, could produce a 
significant reduction in rehospitalization rates from 58% to 
41% and shortened hospital stays from 78 to 39 days.52 The 
researchers suggest that the effective therapeutic elements 
of psychoeducation programs were therapeutic interactions 
(relationships), clarification (about schizophrenia and its 
causal attributions), and enhancement of coping competence 
and skills for the illness and patient’s life problems.
Most successful or effective psychoeducation programs 
have consisted of a wide coverage of patient needs and 
concerns in relation to the illness and its treatment and 
self-management. Bisbee and Vickar53 recommended that 
psychoeducation topics for schizophrenia include clear orien-
tation to patienthood, adequate and up-to-date knowledge of 
the illness and its care, theories and practices of medication, 
stress and illness management, effective communication and 
coping skills, satisfactory family relationships and interper-
sonal interactions, maintenance of good nutrition and health, 
and prevention of relapse and substance use. Although many 
psychoeducation programs have shown positive effects in 
terms of relapse prevention, increase of knowledge about 
the illness, and medication compliance among people with 
schizophrenia, there are still uncertainties about their effica-
cies in other important patient outcomes (eg, global function-
ing, insight into the illness and its treatment, and quality of 
life), especially in the longer term (ie, .2 years).52,55 More 
well-structured and standard psychoeducation programs 
should be designed and evaluated, with clear and detailed 
descriptions of their contents, to help mental health pro-
fessionals implement evidenced-based mental health care 
intervention and services for people with schizophrenia and 
their families.
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Family (or family-based)  
intervention
Schizophrenia can cause disabling experiences and distress 
to both people with schizophrenia and their families. Because 
family members are the main carers for patients in the com-
munity, the effect of caring for patients is often described 
as burdensome and includes the different subjective and 
objective aspects of physical, emotional, or psychological 
and socioeconomic health problems.4 Although different 
terminology is used for family-focused interventions in 
schizophrenia, Pharoah et al6 suggested the terms psy-
chosocial, psychoeducation, and behavioral management 
approaches to family interventions generally refer to those 
interventions in an individual or group format, in which 
patient and family members meet together, there is a skills 
acquisition component in addition to a didactic teaching 
element, and the primary aim of the program is to reduce 
patient relapse and readmission. However, family education, 
consultation, support, and counseling and relatives’ groups 
usually refer to interventions directed at family members 
alone (excluding the patient), and their primary focus is on 
family members’ needs. Since the early 1960s there has been 
a better understanding of the effects of the family’s expressed 
emotion in relation to the course of the illness and relapses, 
resulting in the increased study of family partnership in 
schizophrenia care over the last three decades.56
The National Institute for Clinical Excellence, in their 
clinical guidelines to National Health Service trusts in 
England and Wales,3 as well as the Schizophrenia Patient 
Outcomes Research Team Programs for treatment and 
research on schizophrenia in the United States,57 recommend 
that pharmacological treatment for people with schizophrenia 
be better integrated with other psychological, social, and 
educational interventions at the earliest opportunity. Working 
with families appears to be one of the most effective ways of 
delivering community-based intervention to these patients.
There are several other reasons for providing interven-
tions to families of people with schizophrenia. First, studies 
on expressed emotion, which refers to the critical or emo-
tionally overinvolved attitudes and behavior displayed by 
family members toward their relative with schizophrenia, 
has revealed that family dynamics and emotional climate 
affect the recurrence of positive symptoms, and therefore 
the course of the illness.58 Although a supportive and caring 
family environment can be induced through family education 
and partnership in treatment planning and implementation, 
an enhanced competence and ability of the families to 
detect and notify mental health professionals about any 
warning signs of relapse are crucial for relapse prevention 
in schizophrenia,22,59 to avoid contributing to long delays in 
treatment and to achieve early recovery. Second, having an 
intimate relationship with a relative with schizophrenia and 
providing care for such a person can place a great burden on 
family members. Reducing caregiver burden is an important 
goal of family support and care that, in turn, can help these 
carers take better care of their loved ones while maintain-
ing their own health and well-being. Last, high levels of 
expressed emotion and perceived burden within a family 
can have a negative effect on a patient’s illness, increasing 
their vulnerability to relapse.60 The intimate relationship and 
interactions between patients with schizophrenia and their 
family members warrant the application of family-centered 
interventions to improve both the families’ and patients’ 
ability to cope with the illness management.
Recent reviews of more than 50 controlled trials 
(.4,800 patients) of different modes of family-based inter-
vention from 1980 to 2010, such as family behavioral man-
agement and psychoeducation programs,6,61 reveal that family 
intervention, as an adjunct to drug treatment and routine care, 
can significantly enhance family members’ knowledge about 
the illness, reduce family burden and patients’ relapse up to 
2 years, and improve patients’ medication compliance. Both 
single-family and/or multiple-family group programs, lasting 
from 3 months to 3 years and consisting of a wide variety of 
psychotherapeutic techniques, were associated with fewer 
patient relapses and rehospitalizations, with rates about half 
those of patients receiving routine psychiatric care. Even 
though these families may have different health needs and 
expectations across the course of the illness, they have a few 
common needs for psychoeducation, including understanding 
about the nature of the illness, ways of coping with psychotic 
symptoms, methods of medication and illness management, 
psychological support and practical assistance during times 
of crisis, and means of getting links to community mental 
health services.3,19
Family psychoeducation, which has been derived from 
stress reduction and coping models and other psychologi-
cal theories such as cognitive–behavioral, social learning, 
and crisis theories,2,7 is the most frequently used model of 
family-based intervention for people with schizophrenia in 
both Western and Asian countries. As these psychoeducation 
programs mainly focused on the patient’s mental condition, 
the studies paid little attention to the family’s burden or the 
family members’ perceptions of their problems and needs. 
Treatment teams seek to establish a collaborative relation-
ship with the family to share the burden of managing the 
Neuropsychiatric Disease and Treatment 2013:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1470
Chien et al
illness and working toward patient recovery.62 Behavioral 
family management is another frequently used approach 
to family-based intervention for schizophrenia. Developed 
by McFarlane et al55 in the United States, the program uses 
family education, training in communication skills, and prac-
tice in problem solving and has been delivered successfully 
across countries in the context of multiple-family groups via 
10 sessions during a 3-month period.63–65 It has been shown 
to be effective in reducing patients’ symptoms, promoting 
remission, strengthening social functioning, and reducing 
family burden.
Other approaches to family-based intervention for schizo-
phrenia care include professional-led or peer-led multiple-
family support and education groups (aimed at providing 
continued education, caregiving skills training, and support 
for these families), family-aided ACT (providing family crisis 
intervention and case management for those with chronic or 
treatment-resistant schizophrenia), and family consultation or 
supportive counseling (using an individualized approach of 
support and adaptation training for a family member or the 
whole family).48,64 Most family education approaches adopt a 
strengths perspective, in which families are encouraged and 
assisted in developing their stress management and coping 
skills and improving their psychological well-being and abil-
ity to adapt to dealing with their relative’s illness.64
Comparing the effects of different models of family inter-
vention on patient and family outcomes, studies in mainland 
China (eg, Chien and Wong65 and Li and Arthur66), Europe 
(eg, Stengård),67 and the United States (eg, Dyck et al68 
and McFarlane et al55) have consistently demonstrated that 
family psychoeducation and/or behavioral approaches to 
intervention spanning at least 10 sessions over the course of 
6 months are more effective and have a relatively long-lasting 
effect (ie, .2 years) in terms of preventing patient relapse 
than individual psychosocial treatment or medication alone. 
However, the psychoeducation and behavioral approaches to 
intervention, as described by researchers in previous studies, 
expressed variety of content, format, and techniques. The 
common elements in several of the more effective family 
psychoeducation programs include social support, education 
about the illness and its treatment, guidance and resources 
during a crisis, and training in problem solving.2,69 However, 
little is known about the major therapeutic components of 
psychoeducation and other psychosocial family-based inter-
ventions for schizophrenia. With better understanding of 
these crucial therapeutic elements within family intervention, 
it may be possible to develop a more consistent, reliable, 
and effective family intervention program for people with 
schizophrenia. The specific effects of family intervention 
on family members’ psychosocial needs such as family 
functioning, psychological distress, and burden of care and 
home-based patient care have not been studied adequately; 
thus, data are few and equivocal.6
Anderson and Adams70 and Drake et al71 have suggested 
there are difficulties in employing family intervention in 
everyday clinical practice, with groups of patients with 
schizophrenia in receipt of community care because of 
inadequate mental health care services, staff training, and 
resources. Multiple-family groups may have very high 
noncompliance or attrition rates resulting from the group 
members’ time constraints on attending groups because of 
their work and busy domestic lives, as well as the inconve-
nience of transport and meeting times. In addition, they may 
not be able to arrange alternative care for the patient when 
attending the group, and running a family group requires a 
highly skilled and experienced therapist for effective man-
agement of patients’ psychotic symptoms and disturbing 
behaviors and/or those highly distressed family carers.19,72
Stanley and Shwetha73 suggest that an integrated thera-
peutic approach to family-based intervention consisting of 
multiple components such as pharmacotherapy, psychosocial 
therapies, and spiritual therapy is more successful in improv-
ing the mental status and psychosocial functioning of people 
with schizophrenia, together with reducing family burden and 
increasing quality of life in their family caregivers.
Social skills training
Social skills represent the constituent behaviors that, when 
combined in appropriate sequences and used with others in 
appropriate ways and social contexts, enable a person to have 
the success in daily living that reflects social competence.74 
A lack of social skills is one of the major deficits in psycho-
social functioning among people with schizophrenia.74 It can 
provoke stressful interactions with the social environment and 
lead to social withdrawal and isolation. Social skill training 
originated from the social skills model of Robert Liberman75 
and consists of three main components: receiving skills (social 
perception), processing skills (social cognition), and sending 
information skills (behavioral responding or expression). In 
contrast, social competence generates social resources and 
improves community integration and role functioning.76 This 
training, practiced mostly in groups, aims to enhance patients’ 
social competence in terms of interpersonal and communica-
tion skills, illness management, community reintegration, 
workplace social skills, and instrumental activities of daily 
life. Although the content of the current training programs 
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can vary, a common set of training strategies found across 
them included goal setting, behaviorally based instruction, 
role modeling, behavioral rehearsal, corrective feedback, 
positive reinforcement, and homework to foster generaliza-
tion of skills.77
When patients with schizophrenia have been equipped 
with skills to deal with stressful life events and daily has-
sles, they are proficient in solving their life problems and 
challenges, and consequently, those life stressors are less 
likely to trigger exacerbations or social decompositions of 
schizophrenia.78 Social skills compliance can also expand 
patients’ participation and partnership in treatment decisions 
and partnership, as evidenced by its effectiveness in teaching 
medication self-management skills. When the patients learn 
how to properly use medication, they are more in control of 
their own illness, experience greater responsibility for their 
treatment, and achieve greater insight into their illness.79 
Three critical reviews of more than 50 controlled trials of 
social skills training for schizophrenia and other psychotic 
disorders suggest that participants in diverse community and 
in-patient mental health care settings can retain their improve-
ments in knowledge and behaviors in different aspects 
of learned social skills for up to a 2-year follow-up.80–82 
Therefore, social skills training programs have demonstrated 
positive effects on workplace and social functioning general-
ized to different community settings.80 However, the results 
of most studies during the last three decades are discouraging 
for transferring the learned social skills (particularly those 
complex steps/procedures and high stimulus gradients) to 
participants’ real environments. Therefore, recent studies 
suggest that incorporating generalization techniques into a 
skill training program, thus creating opportunities for using 
the skills in the living environment and receiving appropri-
ate feedback and social reinforcements, would increase the 
likelihood of skill transfer to everyday life situations.82
Of the psychosocial interventions for schizophrenia 
discussed in this article, social skills training has the longest 
history, having been used to help patients learn to cope with 
interpersonal relationships since the 1960s. Although most 
studies of this training in the 1980s and 1990s reported 
considerable effects on improving patients’ living skills and 
social adjustment, more recent studies have failed to provide 
evidence to support its benefits for chronic schizophrenia 
sufferers, particularly in reducing positive symptoms and 
improvements in community functioning and other complex 
social skills such as assertiveness and job-related skills.83 
One recent meta-analysis of 22 randomized controlled tri-
als conducted between 1973 and 2007 concluded that such 
training programs can produce a moderate but significant 
and consistent improvement in social functioning (effect 
size, 0.41–0.52) and negative symptoms (effect size, 
0.40–0.47) of people with schizophrenia, and considerably 
reduce rehospitalization rates over the course of 1–2 years 
of follow-up.77 By using performance-based measures, the 
participants’ mastery of social skills and daily living skills 
(effect size, 0.48–0.52) could be consistently and sustainably 
maintained during the follow-up period. However, these 
training programs could not demonstrate any significant 
effect on other patient outcomes, such as mild improvements 
in general psychopathology, relapse prevention and positive 
symptoms, and cognitive function.75–78
The role of social skills training has also been indicated 
as important in combination with other psychosocial inter-
ventions, such as cognitive remediation, to generalize the 
learned skills to real-life accomplishments in social and 
vocational duties. For instance, in the Cognitive Enhancement 
Program developed by Hogarty and Flesher,84 patients with 
schizophrenia were involved in practicing structured social 
interactions weekly, solving social dilemmas in real life, and 
appraising affect and social contexts, conversations with and 
feedback from other patients, and coaching and home assign-
ments to implement skills in life problems or situations. With 
concurrent use of computer-aided neurocognition and social 
cognitive remediation (to improve attention, verbal learn-
ing, memory, and social adjustment and competence), the 
participants receiving social skills training could significantly 
improve their participation in employment situations and 
mastery of living and working skills. For achieving an optimal 
effect of work and living skills accomplishment, innovative 
combinations of conventional rehabilitation programs and 
social skills training and/or other psychosocial interventions 
should be considered. Similar to the results of most recent 
reviews,80,85 Dixon and his patient outcomes research team 
recommend that social skill training can be used as an adjunct 
to cognition and community skills training to produce synergic 
effects in the performance-based social and community skills 
and functioning of people with schizophrenia.2 More research 
is also needed to examine the predictors of therapeutic effects 
or responses to social skills training in schizophrenia, as well 
as the durability and generalizability of its benefits.
ACT
ACT is a persistent, intensive outreach or case man-
agement model that targets diff icult-to-engage or 
refractory schizophrenia. This treatment approach was found 
to be particularly effective for those who make particularly 
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high use of inpatient services, have a history of poor engage-
ment with services leading to frequent relapse and/or social 
breakdown (eg, as manifested by homelessness, noncompli-
ance with treatment, social withdrawal, loss of contact with 
routine services, or seriously inadequate accommodation), or 
need urgent or immediate access to assistance or support in 
crises.86 These treatment teams are characterized by very low 
staff-to-patient ratios (eg, 1:10), high frequency of contacts/
visits, provision of comprehensive medical and social advice 
in a home or supervised care environment, and multidisci-
plinary care with 24-hour coverage and shared caseloads. 
Although frequent home visits can facilitate medication com-
pliance, crisis intervention, and establishment of therapeutic 
relationships, health assessment of patients and their families 
is more accurate and comprehensive because treatment team 
members can observe patients’ behaviors directly rather than 
depending on patients’ self-reporting. Bond et al87 suggested 
that every community have ACT teams with a capacity to 
serve 0.1% of the general population or 20% of all patients 
with severe mental illness.
In the 1990s, ACT conducted in the United States was 
shown to reduce patients’ hospitalization and increase com-
munity service use at a reduced cost.88,89 Bond et al’s study87 
in Australia reported that ACT not only reduced patients’ 
symptoms and rehospitalizations but also improved their 
housing and quality of life when compared with routine 
care. Nevertheless, recent studies have suggested that most 
benefits of ACT could not be replicated outside the United 
States; for example, in the United Kingdom89,90 and other 
European countries,91 except for maintaining contact with 
these patients. The United Kingdom studies indicated that 
ACT did not demonstrate any consistent positive effect on 
social adjustment and functioning. In addition, the dynamic 
and fluid nature of its service provision causes difficulty in 
identifying or defining the therapeutic components contribut-
ing to positive patient outcomes.
However, in agreement with two systematic reviews, 
Clarke et al,92 in their review on 25 randomized controlled 
trials with 3–36 months’ follow-up, suggest that ACT can 
substantially reduce psychiatric hospitalization by 78% (74% 
of the trials reviewed), increase housing stability (67%), and 
moderately improve positive symptoms (44%) and quality 
of life (58%) among patients with schizophrenia and other 
severe mental illnesses. In contrast, it has been suggested 
that ACT has little effect on patients’ social and vocational 
functioning, substance use, and satisfaction with services. 
Several British studies of ACT have indicated disappointing 
results, and thus Marshall and Creed93 conclude that low 
caseload ratios do not necessarily result in better patient 
outcomes but, rather, specific organizational characteristics 
of the ACT model (eg, multidisciplinary collaborations, daily 
team meetings, comprehensive needs assessment, and shared 
caseloads and responsibilities) are essential and important to 
its effectiveness. More evidence on the efficacy and practice 
standard or the program structure and content of ACT should 
be found before it can be widely used as an evidence-based 
intervention. As ACT targets individualized management and 
intensive care for difficult-to-engage or refractory patients 
with schizophrenia or other severe mental illness, one of 
the major barriers to the development of this treatment 
model may be the absence of valid methods to determine 
these patients’ health needs. Such tiered case management 
approaches can work best when the functions and roles of 
multidisciplinary teams are carefully organized.87,88
Relative efficacy  
of different approaches  
to psychosocial intervention
From the literature reviewed between 1995 and 2008, the 
estimated efficacy of the five main approaches to psychoso-
cial intervention for schizophrenia (ie, CBT, psychoeduca-
tion, family intervention, social skills training, and cognitive 
remediation) is presented in terms of the effect sizes on 
two of their most commonly reported patient outcomes. 
The effect sizes of CBT in terms of relapse (over the course 
of 24 months) and positive symptoms (using Hedger’s g) 
are 0.20–0.52 and 0.19–0.50, respectively,40,94 and those of 
psychoeducation are 0.25–0.50 and 0.21–0.48, respectively.50 
For family intervention, the effect sizes in terms of men-
tal state and family burden are 0.21–0.45 and 0.28–0.50, 
respectively.6,63 In addition, the effect sizes of social skills 
training based on improvements in interpersonal skills and 
community functioning are 0.58–1.12 and 0.45–0.89, respec-
tively, whereas those of cognitive remediation in terms of 
cognitive functioning and social behaviors are 0.13–0.70 and 
0.28–0.50, respectively.26,95
Table 1 summarizes the mean weighted effect sizes of 
the controlled trials (between 2000 and 2012) of three most 
commonly used modalities of psychosocial interventions, 
namely, CBT, family intervention, and psychoeducation, 
in terms of four reported outcomes (positive and negative 
symptoms, level of functioning, and relapse rate). CBT has 
indicated moderate effects on positive and negative symp-
toms and functioning (mean effect sizes, 0.40–0.42) during 
a 12-month follow-up, whereas psychoeducation could 
have moderate effects on positive symptoms and relapse 
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care to improvements in functioning, collaborative decision-
making, and recovery from the illness.22,69
For better understanding of the clinical evidence regard-
ing patient-focused perspectives used in current research, 
a literature search was conducted, mainly using the databases 
of CINAHL, MedlinePlus, and PubMed (from 1982–2013). 
Several key words were used independently or in combina-
tion to search all the literature published in English, including 
“schizophrenia,” “intervention,” “treatment,” “quality of 
life,” “patient perspective or satisfaction,” “service/treatment 
acceptability,” “adherence,” and “uptake.” The inclusion 
criteria of the clinical research were experimental, quasi-
experimental, or longitudinal cohort studies with at least a 
single outcome in terms of patient-focused perspectives (eg, 
patients’ quality of life, treatment adherence and satisfaction 
with services received), patients primarily diagnosed with 
schizophrenia or its subtypes, brief and full description of the 
interventions or services received, and clear description of the 
outcome measures used. From 260 studies initially retrieved 
from the databases, only 25 met all of these criteria and are 
included in this section for discussion. These 25 studies were 
mainly randomized controlled trials, although three used a 
longitudinal, prospective cohort design or mixed research 
methods. Surprisingly, the outcome measures in terms of 
patient-focused perspectives were mainly medication or 
treatment adherence (n = 17), and only a few studies mea-
sured patient satisfaction (n = 7), social functioning (n = 4), 
Table 1 Mean effect sizes of three psychosocial interventions for schizophrenia on selected outcomes during a 12-month follow-up
Outcome (over 
12 months) and 
intervention
Studies  
(2000–2012), n
Total  
sample size
Mean  
weighted  
effect size
95%  
confidence 
interval
Heterogeneity 
test (df), P
Positive symptoms
 CBT 20 .1,100 0.42 0.30–0.54 59.2 (19)**
 Fi 8 .400 0.30 0.19–0.39 41.9 (7)*
 Pe 21 .1,200 0.45 0.30–0.55 64.1 (20)**
Negative symptoms
 CBT 14 .600 0.40 0.30–0.50 60.8 (13)**
 Fi 4 .250 0.28 0.21–0.35 28.2 (3)
 Pe 18 .900 0.29 0.20–0.39 38.3 (17)*
Functioning
 CBT 14 .800 0.36 0.27–0.49 53.8 (13)**
 Fi 10 .600 0.34 0.24–0.43 48.2 (9)**
 Pe 20 .1,300 0.38 0.26–0.50 60.3 (19)**
Frequency of relapse
 CBT 22 .1,300 0.42 0.30–0.50 60.8 (21)**
 Fi 15 .1,000 0.40 0.28–0.50 56.2 (14)**
 Pe 25 .1,600 0.49 0.38–0.59 78.3 (24)***
Notes: Statistical significance is represented by *P , 0.05; **P , 0.01; ***P , 0.005. Data obtained from studies on CBT: Dickerson,94 Lecomte et al,27 Penn et al,97 Pinninti 
et al,98 Rathod et al,96 and wykes et al;26 Fi: Bäuml et al,99 Pharoah et al,6 Schultz et al,100 and Lucksted et al;63 and Pe: Rummel-Kluge and Kissling,7 Bisbee and Vickar,53 
Lincoln et al,101 and Xia et al.50
Abbreviations: CBT, cognitive behavioral therapy; FI, family intervention; PE, psychoeducation.
prevention (mean effect sizes, 0.45 and 0.49, respectively). 
For family intervention, the effects are more prominent on 
improvement of patient functioning and relapse rate (mean 
effect sizes, 0.34 and 0.40, respectively). Most consistently, 
these three kinds of interventions have demonstrated signifi-
cant reduction of relapse during a 12-month follow-up (mean 
effect sizes, 0.40–0.49).
Patient-focused perspectives
During the last few decades, approaches to treatments of 
people with schizophrenia and their outcomes have mainly 
been judged and directed by paternalistic views of medical or 
other mental health care practitioners. Despite the emergence 
of psychosocial interventions or other alternative treatments, 
there is limited attention and minimal efforts to plan for these 
interventions and evaluate their outcomes on the basis of the 
perspectives of these patients.69 From the literature review 
of the psychosocial interventions and pharmacological 
treatments (in part I of “Current approaches to treatments 
for schizophrenia spectrum disorders,” by Chien and Yip1), 
limited evidence was found on the efficacy of interventions 
for schizophrenia based on patient-focused perspectives, 
in which the patients’ quality of life, satisfaction with and 
acceptability to the service received, and adherence to and 
uptake with the interventions offered to them are targeted. 
In contrast, the focus in treatment of these patients has been 
moving from symptom control and chronic and maintenance 
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and quality of life (n = 8) as secondary outcomes. Among 
those with at least a 1-year follow-up (n = 18), quality of life 
and treatment adherence were the most frequently measured 
patient-focused outcomes.
The 25 studies reviewed with outcomes in terms of 
patient-focused perspectives mainly evaluated the efficacy 
of adherence therapy, the integrated treatment approach, or 
second-generation antipsychotics for people with schizo-
phrenia (eg, Anderson et al,102 Gray et al,103 Lindenmayer 
et al,104 Kilian et al,105 and Wiersma et al106) and were con-
ducted in the United States or Europe. Five selected recent 
studies with outcomes measured in terms of patient-focused 
perspectives,102,103,106–108 mainly including patients’ quality 
of life, satisfaction with services, and medication adher-
ence, are summarized in Table 2. The selected studies are 
also discussed here to better understand to what extent the 
patient-focused perspectives are being considered in recent 
schizophrenia research. Several reviewed clinical trials that 
evaluated the effects of medication adherence therapy using 
the techniques of CBT and/or motivational interviewing109 
revealed mixed results on patients’ perceived quality of life. 
Gray et al103 compared the effects of adherence therapy and 
routine psychiatric care for people with schizophrenia on 
improving medication compliance, quality of life, and several 
other outcomes in a 52-week European multicenter random-
ized controlled trial. The study identified no significant dif-
ferences between the adherence therapy group (n = 204) and 
the control group (n = 205) on the patients’ quality of life 
and psychopathology during a 1-year follow-up. Puschner 
et al110 found that psychotic patients’ perceived health-related 
quality of life after undertaking adherence therapy might 
have been compromised with their symptom severity and the 
adverse effects of the antipsychotics used. In another adher-
ence therapy trial, Anderson et al102 explored the efficacy, 
acceptability, and patient satisfaction with the adherence 
therapy used among a small sample (n = 26) of patients with 
schizophrenia in the United States. The results showed that 
the patients (n = 12) reported a high degree of acceptability 
and satisfaction with the 8-session adherence therapy even 
though they did not show significant improvements in mental 
state and medication adherence at the post-tests when com-
pared with the routine-treatment group (n = 14). In addition, 
most of the reviewed studies of adherence therapy for people 
with schizophrenia found that over a longer-term follow-up, 
these patients could show neither significant improvements 
in their level of adherence to medication and quality of life 
nor satisfactory control or reduction of psychotic symptoms, 
particularly negative symptoms.
An integrative approach to treatment for people with 
chronic schizophrenia and persistent hallucinations (n = 31) 
has been evaluated in a randomized controlled trial to ascer-
tain its effect on their quality of life and social functioning 
compared with routine psychiatric outpatient care (n = 32).106 
This approach integrates CBT, coping skills training, 
community rehabilitation services, and crisis intervention 
into a family-focused intervention, as well as the use of 
antipsychotic medication. The treatment group indicated 
significantly better quality of life and social functioning 
than seen with those patients receiving routine care at the 
8- and 18-month follow-ups, indicating that this integrated 
approach appeared to be effective for people with chronic 
schizophrenia in a medium-term follow-up. Recently, there 
have been an increasing number of integrative treatment 
programs for these patients, but there is no systematic and 
empirical evidence of their effects, particularly during a 
longer follow-up period. Although some of these innovative 
programs were developed from the service-users’ or patients’ 
perspectives or based on a collaborative decision-making 
model, their components for the integration of schizophrenia 
treatment varied considerably in terms of structure, format, 
and content, making it difficult to identify the active and 
therapeutic components contributing significant benefits to 
patients, if any. It is recommended that more research be 
conducted to test the efficacy of these integrative models 
of care in terms of both illness-related and longer-term 
patient-focused outcomes and that the therapeutic elements 
contributing to patient recovery from schizophrenia be 
explored.
It is interesting that a few comparative studies were 
conducted in the 1990s to identify the effects of first- and 
second-generation antipsychotics on the health-related 
quality of life of people with schizophrenia.111–113 Similar 
to other controlled trials of the effects of antipsychotics in 
schizophrenia,98,105 none of these studies could support the 
superiority of the second-generation (atypical) antipsychot-
ics in improving patients’ quality of life and their cognitive 
and social functioning. In two controlled trials with 227 and 
307 patients with schizophrenia,104,114 second-generation 
antipsychotics could not demonstrate any better quality of life 
or cost-effectiveness than different types of first-generation 
antipsychotics during more than a 1-year follow-up. 
Nonetheless, more recent research and reviews on long-
term use of second-generation antipsychotic therapy such as 
quetiapine115,116 and risperidone104 have shown that it was a 
more tolerated, acceptable, and satisfactory treatment than the 
other previously prescribed first-generation antipsychotics. 
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It is recommended that the perceived benefits and other 
patient-focused outcomes of quetiapine, risperidone, and 
other newly introduced antipsychotics, compared with other 
second-generation antipsychotics, be the subject of further 
research. Given that there is promising evidence of the effects 
of the emerging integrative approaches to different combina-
tions of single and multiple psychosocial interventions as 
adjuncts to antipsychotics, it is more important to examine 
how these innovative, integrative treatment approaches can 
contribute to high-quality patient-centered care, and thus 
positive outcomes from a patient-focused perspective from 
immediately after completion of the intervention to a long-
term follow-up.
Treatment adherence refers to the degree to which an 
individual patient is following their clinical prescription or 
the treatment instructions of a care provider; for example, 
taking medication and modification of diet and lifestyle 
have drawn significant attention in the schizophrenia litera-
ture.117,118 Although there is no specific means of maximizing 
the level of treatment adherence among people with schizo-
phrenia that is recommended by recent research, various 
factors influencing such adherence have been identified; for 
example, social support, encouragement, and supervision 
from family members or significant others119 and a good 
working or helping alliance with patients in their treat-
ment planning and decision-making.108 Results of a recent 
controlled trial of a family supervisory treatment program 
in a high-income population in Pakistan indicated that by 
engaging the family members as key care supervisors to 
administer and supervise the medication, patients with 
schizophrenia could significantly improve their medication 
adherence, psychotic symptoms, and overall functioning dur-
ing a 1-year follow-up.120 Good working alliances between 
patients and mental health professionals are considered an 
important predictor of treatment adherence or compliance: 
the longer a patient stays in a therapy with a favorable and 
therapeutic alliance, the better the patient-focused outcomes 
such as satisfaction and adherence to treatments and services 
received.121 It has been confirmed by a naturalistic, formative 
evaluation of cognitive remediation therapy in 49 people 
with schizophrenia that working alliance was associated 
with fewer complaints regarding treatment received and 
more improvement in treatment adherence and outcome.122 
Nevertheless, most studies on treatment adherence in 
schizophrenia (except antipsychotic trials) are limited by 
being descriptive and exploratory in nature and having a 
smaller sample size and/or nonrandomized, single, or non-
equivalent comparison groups; as a result, they are unable 
to demonstrate consistent and conclusive evidence on how 
different treatment approaches could address this important 
patient-focused outcome.
Although the evidence on patient-focused perspectives 
or their related outcomes in schizophrenia treatment is pre-
liminary and inconclusive, Cañas et al123 recommended that 
patients’ individual health needs and associated risk factors 
influencing nonadherence to treatments should be carefully 
considered in practice to improve treatment adherence and 
patient outcomes in schizophrenia. Personalized treatment 
strategies should be designed and delivered in mental health 
care, incorporating patients’ mental and psychosocial health 
conditions, backgrounds ,and preferences into their treatment 
plan. In addition, the active involvement of family caregivers 
in treatment planning and delivery, together with effective 
communication among staff members, patients, and family 
members, should be considered to optimize the continuity 
of schizophrenia care in the community.
Few studies have been conducted to evaluate the effect 
of interventions on the quality of life, patient satisfaction, 
acceptability, and adherence of people with schizophrenia. 
Some studies had a small sample size that limited the gen-
eralization of the results, and some potentially effective 
interventions require more evidence to support their use in 
practice. Hence, there is a great need for much more research 
to identify the significance of patient-focused perspectives in 
planning and evaluating strategies in treatments and to exam-
ine how each approach to treatment can improve the longer-
term, patient-focused outcomes of schizophrenia care.
Recommendations for best practice
With the literature review in this article and that of part I1 
for an overview and medical approaches to treatments for 
schizophrenia, we provide a better understanding of cur-
rent evidence and several limitations regarding different 
treatment modalities for this severe mental illness. A few 
implications for evidence-based practice and research are 
seen. First, antipsychotics and their combined use with other 
psychotropic drugs are effective in reducing relapse and 
psychiatric symptoms, particularly positive symptoms; in 
contrast, there are great variations of treatment responsiv-
ity, targeting effects, and adverse effects across individual 
patients with schizophrenia.124 With new antipsychotics and 
medication regimens continuously introduced in the treat-
ment of schizophrenia, it is important and essential to conduct 
more clinical trials to confirm and select the ones with the 
best antipsychotic effect and minimal adverse effects across 
patients. More research is also needed to provide data on the 
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associations and predictions of specific dose ranges of each 
effective antipsychotic with the treatment responses of vari-
ous patient groups, based on individual clinical and illness 
characteristics.
Second, in view of limiting the first-line treatment to 
medications, treatment of schizophrenia cannot fully make 
use of emerging knowledge about the etiological, neuropatho-
logical, and clinical nature of the illness and may therefore 
fail to develop more effective treatments based on this new 
knowledge. With our current understanding of the molecular, 
functional, and pathophysiological nature of schizophrenia, 
new pharmacological and treatment approaches targeting 
specific stages of pathogenesis and groups of symptoms of 
the illness may prevent illness progression at different stages 
and offer the possibility of personalized treatments based on 
an individual’s characteristics and illness condition.47 When 
applied to clinical treatment, their ability to overcome the 
pitfalls of current treatment modalities in improving the cog-
nitive and functional abilities of different groups of patients 
with schizophrenia and its subtypes should be examined. 
Patient-focused perspectives in their own treatment planning, 
preference, and satisfaction, as well as outcome measurements, 
should also be enhanced to address their longer-term need for 
recovery and a better quality of life. To facilitate personal-
ized treatment for people with schizophrenia, it is recom-
mended that those treating them engage in collaborative and 
informed decision making by evaluating the treatment needs 
and preferences of every individual patient, the effects and 
limitations of current treatments they are receiving, and alterna-
tive treatment options at different stages of the illness.
Third, the clinical evidence on the efficacy of other 
approaches to medical treatment for schizophrenia is weak 
and inconsistent. They are more effective when applied as 
an adjunct to antipsychotics and targeted at specific illness 
conditions such as those with catatonic, strong suicidal, and 
treatment-refractory states. The efficacy of these alternative 
medical treatments, and their combined use with medication 
and psychosocial interventions, should be further studied to 
augment their optimal actions or effects in specific groups 
of patients with schizophrenia.
Fourth, with increasing evidence that psychosocial inter-
ventions are effective in relieving these patients’ psychotic 
symptoms and improving their functioning, some of these 
interventions are therefore recommended as an indispensable 
component of the treatment options available in standard care 
for promoting patient recovery from schizophrenia. However, 
their applications and potential effects on schizophrenia 
sufferers have been hindered by the limited access to and 
availability of the most suitable and effective treatment 
options and inadequate preparation for their consistent and 
appropriate use in mental health care services. Greater efforts 
are needed to better integrate different interventions into the 
existing services and better equip mental health professionals 
psychologically and technically for implementation of these 
interventions in usual practice. Research should also be con-
ducted to examine the therapeutic components of effective 
psychosocial interventions, which are limited and seldom 
explored. Better understanding of the active ingredients of 
each of these interventions could enhance the synergy of 
their combined use, and thus their cost-effectiveness in the 
treatment of schizophrenia.
Fifth, persistent negative symptoms and progressive 
cognitive impairments are major concerns for the profound 
functional disability and social disintegration of people in 
the later stages of schizophrenia. Current treatments have 
had limited efficacy on these illness-related problems. New 
pharmacological strategies and products such as agents stimu-
lating metabotropic glutamate 2/3 receptors125 and dopamine 1 
receptor and 5HT1A agonists126 have recently been introduced 
in adjunct to antipsychotics, with some evidence of their abil-
ity to reduce negative symptoms and cognitive impairments, 
respectively. More research on new pharmacological strategies 
based on the current ones is needed to combat these two major 
deficits and concerns in schizophrenia.
Last and most important, it is essential to develop 
community-based and clinical strategies for detecting risks 
and early signs and providing early treatment for people with 
schizophrenia. Population- or community-based assessments 
of risk factors and symptoms are critical for precisely and 
accurately detecting at-risk groups and directing them to the 
most appropriate preventive programs and strategies available 
in community mental health care services. Early detection and 
targeted interventions of the illness can reduce its vulnerability 
progression to the development of more severe behavioral 
and cognitive problems, as suggested by Birchwood et al in 
their critical period hypothesis.127 To differentiate themselves 
from the current usual treatment methods while using a very 
similar approach throughout the course of the illness, future 
schizophrenia treatments should be specific to the critical 
periods and stages of the illness; place more emphasis on 
preventive, risk-identifying, and early-treatment approaches; 
and use highly personalized treatment strategies.
Conclusion
During the last three decades, pharmacological and 
psychosocial treatments for schizophrenia have developed 
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rapidly and evolved across countries, resulting in significant 
effects on patients’ relapse prevention and symptom control. 
Because of inadequate consistency in implementation and 
limited availability and access to different models of effec-
tive treatments, the dissemination of psychosocial interven-
tions as usual practice within mental health services has 
been slow and patchy. Although pharmacological treatment 
has indicated various kinds and levels of adverse effects, 
most currently used psychosocial interventions cannot 
demonstrate wide-ranging or long-term (ie, .18 months) 
effects on patients’ psychosocial and functional outcomes 
and quality of life. In addition, there are wide variations in 
the treatment responses among these patients, resulting in 
an inability to accurately predict the treatment efficacy to a 
particular patient, and in turn making the optimal patient-
focused treatment difficult. In addition, little is known about 
the therapeutic components or mechanisms of most of the 
current psychosocial interventions, through which they can 
produce their effects. With continuous increased under-
standing about the etiology, psychopathology, and clinical 
manifestations of schizophrenia, more effective methods 
and personalized treatment plans are developing or emerg-
ing to allow mental health professionals to better define and 
manage the course of and patient recovery from the illness. 
With better partnership with family caregivers and staff 
training and resources for psychosocial interventions, more 
initiatives in personalized treatments for schizophrenia will 
be seen to address the many unmet health needs of these 
patients, with promising evidence. However, the research 
and service gaps in treatments for schizophrenia discussed 
and revealed in this article (part II) and another one (part 
I) on “Current approaches to treatments for schizophrenia 
spectrum disorders” can provide insight into the strengths 
and weaknesses of current approaches to treatments for 
schizophrenia;1 in contrast, both also can stimulate sugges-
tions and discussions about approaches to implementing 
evidence-based, person-focused therapy for patients in need 
of personalized care.
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